-

$undefined

N/A

(N/A)

Outlook Therapeutics NasdaqCM:OTLK Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.

Location: 111 S. Wood Avenue, Building F, Suite 320, Iselin, NJ, 08830, United States | Website: https://www.outlooktherapeutics.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

86.18M

Cash

7.556M

Avg Qtr Burn

-16.01M

Short % of Float

13.00%

Insider Ownership

38.31%

Institutional Own.

16.81%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Eye disease , Wet age-related macular degeneration	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Wet age-related macular degeneration , Eye disease	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Eye disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Diabetes, Eye disease , BK virus, Adenovirus, Epstein-Barr virus, Human herpesvirus 6, Cytomegalovirus, Diabetic macular edema	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.